JAZZ Q1 2025 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$898M-0.5% YoY

Gross Profit

$793M88.3% margin

Operating Income

-$56M-6.2% margin

Net Income

-$93M-10.3% margin

EPS (Diluted)

$-1.52

QoQ Revenue Growth

-17.5%

Cash Flow

Operating Cash Flow

$430M

Free Cash Flow

$391M

Stock-Based Comp.

$68M

Balance Sheet

Total Assets

$11.5B

Total Liabilities

$7.4B

Stockholders' Equity

$4.2B

Cash & Equivalents

$1.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$898M	$902M	-0.5%
Gross Profit	$793M	$806M	-1.6%
Operating Income	-$56M	$66M	-184.4%
Net Income	-$93M	-$15M	-533.1%

Revenue Segments

Xywav

$345M38%

Epidiolex/Epidyolex

$218M24%

Rylaze/Enrylaze

$94M10%

Zepzelca

$63M7%

High Sodium AG Oxybate Product Royalty Revenue

$49M5%

Defitelio/Defibrotide

$41M5%

Xyrem

$37M4%

Vyxeos

$30M3%

Other Royalty And Contract Revenues

$9M1%

Sativex

$5M1%

Other Products

$5M1%

Ziihera

$2M0%

Geographic Segments

UNITED STATES

$798M89%

Europe

$84M9%

Other Countries

$16M2%